<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04311840</url>
  </required_header>
  <id_info>
    <org_study_id>SAH_Nimodipine</org_study_id>
    <nct_id>NCT04311840</nct_id>
  </id_info>
  <brief_title>Impact of Nimodipine on Sublingual Microcirculation in Patients With Hemorrhage - a Prospective Monocentric Observational Study</brief_title>
  <official_title>Impact of Nimodipine on Sublingual Microcirculation in Patients With Subarachnoid Hemorrhage - a Prospective Monocentric Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Hradec Kralove</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Hradec Kralove</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nimodipine can increase Functional Capillary Density (FCD) as a parameter of the sublingual
      microcirculation in patients with subarachnoid hemorrhage (SAH) compared to patients without
      nimodipine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SAH group - in patients with SAH and documented vasospasms by digital subtraction angiography
      (DSA) of trans-cranial doppler imaging (TCD) of arteria cerebri media nimodipine is indicated
      because it is proven to improve the clinical outcome. The disfunction of cerebral
      microcirculation in rats with SAH has been documented [1-6]. Changes in sublingual
      microcirculation in patients with SAH with documented vasospasms with nimodipine has not been
      described.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Functional capillary density (FCD)</measure>
    <time_frame>One week</time_frame>
    <description>Parameter describing the perfusion of the microcirculation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of perfused vessels (PPV)</measure>
    <time_frame>One week</time_frame>
    <description>Parameter describing the perfusion of the microcirculation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vasospasm occurence</measure>
    <time_frame>One week</time_frame>
    <description>Occurence of vasospasms on angiography and/or transcranial Doppler</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulatory incoherence</measure>
    <time_frame>One week</time_frame>
    <description>Deranged microcirculation in patients on catecholamines</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Subarachnoid Hemorrhage</condition>
  <arm_group>
    <arm_group_label>SAH patients with nimodipine</arm_group_label>
    <description>Patients with SAH receiving nimodipine as prevention of vasospasms and as a nootropic drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAH patients without nimodipine</arm_group_label>
    <description>Patients with SAH not receiving nimodipine as prevention of vasospasms and as a nootropic drug or in whom the drug has been temporarily discontinued.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All adult patients admitted to the neurosurgical ICU with the diagnosis of subarachnoid
        hemorrhage. Might be alert, somnolent or sedated on mechanical ventilation. Might be after
        endovascular coiling or surgical clipping of the aneurysm.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adulthood

          -  ICU admission

          -  diagnosis of non-traumatic subarachnoid hemorrhage

        Exclusion Criteria:

          -  inherited coagulation disorder

          -  rheumatic disease

          -  microangiopathy

          -  patient of representative refusal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David Astapenko, M.D., Ph.D.</last_name>
    <phone>+420608177374</phone>
    <email>david.astapenko@fnhk.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Hradec Kralove</name>
      <address>
        <city>Hradec Králové</city>
        <state>Třebeš</state>
        <zip>50005</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Dostal, M.D., Ph.D., MBA</last_name>
      <phone>+420495833218</phone>
      <email>karim@fnhk.cz</email>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 18, 2019</study_first_submitted>
  <study_first_submitted_qc>March 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2020</study_first_posted>
  <last_update_submitted>March 15, 2020</last_update_submitted>
  <last_update_submitted_qc>March 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nimodipine</keyword>
  <keyword>sublingual microcirculation</keyword>
  <keyword>Side-stream Dark Field imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

